Long-awaited results of GLP-1 trial in Alzheimer’s disease show disappointing results Novo Nordisk’s Phase 3 trials revealed that oral semaglutide failed to slow the progression of disease.+++++

Long-awaited results of GLP-1 trial in Alzheimer’s disease show disappointing results Novo Nordisk’s Phase 3 trials revealed that oral semaglutide failed to slow the progression of disease. https://www.drugdiscoverynews.com/long-awaited-results-of-glp-1-trial-in-alzheimer-s-disease-show-disappointing-results-16865 Weekly Rundown: Former FDA chiefs rebuke vaccine official's push for stricter review standards FDA updates, pharma tariff agreements, gene editing deals, and more led the news this week. https://www.drugdiscoverynews.com/weekly-rundown-former-fda-chiefs-rebuke-vaccine-official-s-push-for-stricter-review-standards-16863 Quantum chemistry meets cancer treatment QDX and Prelude Therapeutics are developing drugs that selectively target the JAK2 V617F mutation, offering hope for patients with myeloproliferative neoplasms. https://www.drugdiscoverynews.com/quantum-chemistry-meets-cancer-treatment-16860 How small molecule tau inhibitors could treat Alzheimer’s disease While amyloid plaques form first, new work suggests targeting tau tangles that spread through the brain could also help the fight against this devastating disease. https://www.drugdiscoverynews.com/how-small-molecule-tau-inhibitors-could-treat-alzheimer-s-disease-16849 A more electric language for biology Bioelectricity is a potent lever for controlling health. What would it look like to treat the body electrically, rather than chemically? https://www.drugdiscoverynews.com/a-more-electric-language-for-biology-16848